NYSE · Healthcare · Financials
Eli Lilly & Co. (LLY) Financial Statements: Income, Balance Sheet & Cash Flow
Revenue, profitability, balance-sheet strength, and cash generation for LLY. SEC filings, statements through Jun 30, 2026.
Section freshness
Prices as of Sep 18, 4:03 PM EDT · Fundamentals checked Sep 20, 8:52 AM EDT · Statements Jun 30, 2026
Financial read
LLY latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Revenue
$22.97B
+47.7% YoY
Net income
$7.09B
-4.1% QoQ
Net margin
30.88%
Balance sheet coverage
LLY balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
0 quarterly · 4 annual rows
Latest period
ANNUAL FY2025
0 quarterly · 4 annual rows
Assets / liabilities
$112.48B
Liabilities —
Cash / debt
$7.27B
Net cash -$35.23B
Equity / working capital
$26.54B
Working capital $20.40B
Financial statements
LLY statement coverage.
Income statement, balance sheet, and cash-flow figures for LLY, with quarterly and annual history in the tables below.
Data last updated
Jun 29, 2026
Income periods
24
Balance-sheet periods
4
Quarterly and annual LLY statements, sourced from SEC filings, statements through Jun 30, 2026.
Financial statement period
LLY statement history
SEC filings, statements through Jun 30, 2026 · Data last updated: Jun 29, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Net income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|
| Q2 FY2026 | $22.97B | $7.09B | 30.88% | +16.0% | -4.1% |
| Q1 FY2026 | $19.80B | $7.40B | 37.36% | +2.6% | +11.4% |
| Q4 FY2025 | $19.29B | $6.64B | 34.41% | +9.6% | +18.9% |
| Q3 FY2025 | $17.60B | $5.58B | 31.72% | +13.1% | -1.4% |
| Q2 FY2025 | $15.56B | $5.66B | 36.39% | +22.2% | +105.2% |
| Q1 FY2025 | $12.73B | $2.76B | 21.67% | -5.9% | -37.4% |
| Q4 FY2024 | $13.53B | $4.41B | 32.59% | +18.3% | +354.5% |
| Q3 FY2024 | $11.44B | $970.30M | 8.48% | +1.2% | -67.3% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total debt | Total equity | Debt YoY |
|---|---|---|---|---|---|---|---|
| FY2025 | $7.27B | $55.63B | $35.23B | $112.48B | $42.50B | $26.54B | +26.3% |
| FY2024 | $3.27B | $32.74B | $28.38B | $78.72B | $33.64B | $14.27B | +33.4% |
| FY2023 | $2.82B | $25.73B | $27.29B | $64.01B | $25.23B | $10.77B | +55.3% |
| FY2022 | $2.07B | $18.03B | $17.14B | $49.49B | $16.24B | $10.65B |
Valuation and returns
- Enterprise value
- $1.07T
- TECHi computed
- Return on equity
- 78.84%
- Market data source · as of 2026-09-20
- Return on assets
- 18.77%
- Market data source · as of 2026-09-20
- Debt / equity
- 1.62
- Current ratio 1.35
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual revenue base
- $65.18B
- Annual statement 2025-12-31
- Annual income base
- $20.64B
- Annual statement 2025-12-31
- Market cap / annual revenue
- 15.77
- Live market value divided by annual revenue
- Market cap / annual income
- 49.81
- Live market value divided by annual net income
Annual sales and income multiple
Market capitalization bridge
TTM valuation multiples
- TTM revenue
- $79.67B
- Trailing twelve months
- Market cap / TTM revenue
- 12.91
- Live market value divided by trailing twelve months revenue
- EV / TTM revenue
- 13.48
- Enterprise value divided by trailing twelve months revenue
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
- Revenue / employee
- $1.59M
- 50,000 employees
- Net income / employee
- $534,220
- TTM net income divided by employees
- Market cap / employee
- $20.56M
- Live value per employee
Growth vs cost pressure
Quarterly margin heatmap
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · ANNUAL FY2025
- Cash & equivalents
- $7.27B
- Total debt
- $42.50B
- Net cash
- -$35.23B
- Net debt position
- Total equity
- $26.54B
Balance sheet detail
- Current assets
- $55.63B
- Current liabilities
- $35.23B
- Inventory
- $13.74B
- Receivables
- $17.76B
- Property, plant & equipment
- $24.68B
- Current debt
- $1.64B
- Long-term debt
- $40.87B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Frequently asked
Common questions.
What financial data is available for LLY?
TECHi shows Eli Lilly & Co.'s income statement, balance sheet, and cash-flow statement by reported period, with each figure attributed to its source. Line items the company does not report are left blank rather than estimated.
How current are LLY's financial statements?
Each LLY statement is labelled with its reported period and source, so you can see exactly which quarter or fiscal year a figure covers and when the data was last updated.
What is Eli Lilly & Co.'s reported net margin?
Eli Lilly & Co. reports a net margin of 33.53% in its latest available fundamentals; the statements below show the revenue and cost lines behind it.